- Thymulin peaks in childhood, starts falling in your 20s, and becomes undetectable by standard bioassay in most people after 60. It is the only thymic hormone made exclusively in the thymus.
- Thymulin requires zinc to be active. Many people over 60 still produce some thymulin but are zinc-deficient, so the peptide circulates as inactive apothymulin. Correcting zinc is the first and most evidence-backed step.
- Research by Eugenio Mocchegiani and colleagues at INRCA in Ancona, Italy showed zinc supplementation in zinc-deficient elderly subjects partially restored detectable active thymulin activity.
- Exogenous thymulin is available as a research peptide and also used in zinc-thymulin formulas for hair loss. No controlled human trials on immune restoration have been completed. Human dosing is not established.
- How fast the thymus shrinks, and how broad a threat list the T-cells it trains can recognise, both vary between people for inherited reasons. That is why two people the same age with the same thymulin level do not have the same immune system.
Your immune system peaked at 12. That is not a metaphor. At that age, your thymus was at full volume and churning out thymulin, the signal your body uses to train every T-cell it produces. By your late 40s, most of that output is gone. By 60, thymulin falls below what the standard blood test can detect in most people. The immune education system your body was born with has effectively shut down.
The approximate age at which thymulin drops below what the standard blood test can detect in most people, based on studies measuring it across the full span of life.
Thymulin (also called FTS, from the French facteur thymique serique, or serum thymic factor) is a 9-amino-acid peptide produced exclusively by the thymic epithelial cells lining the interior of your thymus. It is the only thymic hormone made solely within the thymus itself. When the thymus shrinks with age, thymulin output falls. When output falls, T-cell education degrades. That chain is the core of what immunologists call immunosenescence, the slow decline of immune function after midlife.
This is not an obscure or newly characterized protein. Jean-Francois Bach and Mireille Dardenne at the Institut Pasteur in Paris spent two decades characterizing thymulin, publishing foundational research starting in the early 1970s. The 50-plus years of follow-on work since then is more than most peptides discussed in the longevity space will ever accumulate. What is odd is how rarely thymulin shows up in mainstream discussions of immune aging, even as its cousin Thymosin Alpha-1 gets significant clinic attention. More on why that gap exists later.
Think of your thymus as a military training academy for immune cells. Every T-cell your bone marrow produces has to pass through this academy before it can fight. Thymulin is the curriculum. It is the set of signals that teaches each T-cell what to attack and what to leave alone. When the academy closes, no new soldiers get properly trained. The ones already in service keep working for a while, but the force gets thinner and less adaptable every decade. That is immune aging, stripped of the jargon.
How Fast Does Thymulin Actually Decline With Age?
Faster than most immune markers, and earlier than most people expect. A published study (listed in PubMed as "Distribution of age-related thymulin titres in normal subjects through the course of life") measured thymulin in blood from newborns through elderly subjects. The decline is clean enough that it has been described as one of the better biological markers of thymic ageing available.
Thymulin activity peaks in early childhood and again around puberty. It starts declining through the 20s and 30s as thymic involution, the progressive replacement of active thymic tissue with fat, gets underway. By the mid-40s, detectable active thymulin has dropped to a fraction of peak levels. By age 60, most people in these studies show nothing at all on the test used to measure the active, zinc-carrying form.
| Age Group | Relative Thymulin Activity | What Is Happening |
|---|---|---|
| Birth to age 6 | Rising | Thymus growing rapidly, thymulin output climbing |
| Age 6 to 12 | Peak | Maximum thymic volume and maximum thymulin output |
| Age 20 to 35 | Declining | Thymic involution begins, fat replaces active tissue |
| Age 40 to 55 | Low but detectable | Most thymic tissue replaced, residual output only |
| After age 60 | Undetectable in most subjects | The standard test finds no active thymulin; some switched-off form may remain |
There is an important nuance here. "Undetectable" does not necessarily mean no thymulin is being made. It means the active, zinc-carrying form has dropped below what the test can see. Some peptide may still be circulating in its switched-off form. That distinction is the whole basis of what can be done about it.
The progressive decline of serum thymulin with age parallels the involution of the thymus and constitutes one of the most reliable markers of thymic aging. Its loss precedes many of the functional immune deficits seen in elderly subjects by years to decades, making it a valuable early indicator of immune aging trajectory.
Review of Thymic Peptides and Hormones from Properties to Clinical Application, Springer, 2024
The Zinc Connection Most Thymulin Guides Skip Over
Here is the part that changes the picture meaningfully. Thymulin is biologically inactive without zinc. The peptide circulates in two forms: active thymulin (zinc-bound) and apothymulin (zinc-free). Only the zinc-bound form can engage thymulin receptors on T-cells and trigger the differentiation signals that define thymulin's role.
Zinc deficiency is extremely common in people over 60. Absorption efficiency drops with age, dietary intake often declines, and competition from other minerals increases. Research by Eugenio Mocchegiani and colleagues at INRCA in Ancona, Italy found that in elderly subjects who showed undetectable active thymulin by bioassay, zinc supplementation partially restored detectable thymulin activity. Those subjects still had some thymulin peptide in circulation, but it was traveling as inactive apothymulin. Adding zinc reactivated a portion of it.
The restoration was not dramatic. The studies did not show a return to childhood levels. But they did establish that "undetectable" sometimes means "the cofactor is missing" rather than "the peptide is gone." That is a clinically important distinction because the intervention for one of those scenarios (zinc supplementation) is cheap, safe, and widely available.
Active Thymulin (Zinc-Bound)
Biologically functional. Binds thymulin receptors on T-cells. Directs thymocyte differentiation into mature T-cell subtypes (CD4+, CD8+). This is the form standard bioassays detect and the form that actually does the work.
Apothymulin (Zinc-Free)
Biologically inactive. Circulates without receptor activity. Cannot train T-cells. Not detected by standard rosette-inhibition bioassay. Present in some elderly subjects who test at zero, meaning the peptide is there but the switch is off.
Before assuming complete thymulin failure, checking zinc status is sensible. Serum zinc below 70 mcg/dL in an adult is deficient by most clinical reference ranges. Correcting zinc through supplementation (typically 15 to 30 mg elemental zinc daily, often as zinc bisglycinate or zinc picolinate for absorption) is the most evidence-backed single intervention in thymic aging. It does not restore the thymus to age-12 output, but it may recover meaningful thymulin activity that zinc deficiency was suppressing.
What Happens to Your Immune System When Thymulin Goes to Zero
T-cell production in the thymus does not completely stop when thymulin vanishes. The thymus still generates some T-cells even in its atrophied state. But the quality and variety of the output degrades. Without enough thymulin signal, fewer immature T-cells finish their training and take on the surface markers that make them functional, and more are scrapped as useless or as a risk of attacking the body itself.
The downstream effects accumulate over years. Fewer naive T-cells enter circulation. The ones that do recognise a narrower range of threats, so a new pathogen is likelier to slip past. Regulatory T-cell balance shifts. Cancer immune surveillance weakens. Autoimmune risk increases paradoxically, as immune regulation degrades even while raw immune output falls. The very thing designed to tell your immune system what not to attack becomes less reliable as the machinery that trained it shuts down.
The estimated reduction in functional thymic tissue volume by age 70, based on imaging studies tracking the ratio of active thymic tissue to adipose replacement across age groups from childhood through late adulthood.
A 2024 review article in the Springer journal covering thymic peptide research surveyed 50 years of accumulated evidence and described this pattern across multiple clinical populations, including increased infection susceptibility, elevated cancer incidence, and altered inflammatory tone, all consistent with the thymulin production timeline. The same review highlighted the unusual position thymulin occupies: well-characterized for decades, with a clear biological role, but without completed controlled human trials for supplementation.
This is not hypothetical biology. The elderly immune phenotype, more infections, slower recovery, higher cancer incidence, increased autoimmune activity, is the observable clinical expression of what happens when a lifetime of thymulin-guided T-cell education ends and is not replaced. A 2018 study showed thymulin reduced inflammatory pain in animals, opening a second research direction around pain relief and inflammation, separate from its role in the thymus. That work confirmed thymulin receptors exist outside the thymus, which complicates and enriches the picture of what restoring levels might accomplish.
Three Approaches to Thymulin Restoration (Ranked by Evidence)
1. Zinc Supplementation
The most evidence-backed and immediately practical approach, covered above. Corrects the cofactor deficiency that can suppress whatever thymulin is still being produced. Does not rebuild thymic tissue. Does not restore production to youthful capacity. But in zinc-deficient elderly subjects, the partial recovery of active thymulin from the Mocchegiani group's work is real and replicated.
2. Exogenous Thymulin Peptide
Available from research peptide suppliers as an injectable nine-amino-acid peptide. Research dosing in animal studies ranged widely, often in nanogram-per-kilogram ranges far below what most peptide protocols use. Human translation is genuinely unclear. No controlled human trials on exogenous thymulin for immune restoration have been published with outcome data as of 2026. Compounding clinics offering thymulin typically use 200 to 500 mcg injected under the skin, sometimes in cycles, but those numbers come from practice, not from trials. The regulatory status in the US places thymulin as a research peptide without FDA approval or compounding eligibility under current rules.
3. Zinc-Thymulin Complex for Hair Loss: A Separate Application
This is worth knowing because many people meet thymulin through hair loss clinics rather than immunology. Thymulin receptors sit on the cluster of cells at the base of a hair follicle that controls its growth cycle. Early research, and a US patent on thymulin-like peptides for pain relief, established that the peptide is active outside the thymus. For hair loss, zinc-thymulin formulas applied to the scalp or injected into it have been offered by compounding pharmacies as a treatment for pattern hair loss. The mechanism operates through hair follicle survival and cycling, completely separate from T-cell education. It is mentioned here because it is a real and growing application, not because it overlaps with the immune aging use case.
Why two people the same age have different immune systems
Two people can have identical thymulin levels and very different immune outcomes, because the level is only half the story. The other half is what the T-cells that thymulin trained are able to see.
That part is set by your HLA genes. They build the molecules that hold up fragments of a germ or a damaged cell for a T-cell to inspect. A narrower HLA set means a narrower set of threats your immune system can recognise, whatever your thymulin level is. Nothing in a peptide protocol changes this; it is context for why immune ageing is not one number.
Inflammation is the second factor. IL-6 is one of the body's main inflammation signals, and versions of its control region that keep it running high create an environment that is hard on the thymus cells that make thymulin. If that describes you, the age curve above is an average your own curve probably runs ahead of. What you would do with that: treat the zinc check and the inflammation basics as more urgent, not less, at a given age.
Third, and least actionable, is FOXO3, a gene that switches on cellular repair and stress-defence programmes. Certain versions of it turn up far more often in people who live past 100, and those people hold onto immune function later, including a slower-shrinking thymus. Carriers may still have detectable thymulin past 60. It is a description of your ageing rate rather than something to act on. You can read about how peptide response shifts after 50 including how aging-related genetic variants change your protocol priorities. You can also explore Epithalon and telomere length research, which comes from the same Russian thymic peptide research tradition as thymulin and shows similar longevity-genetics interactions.
For a broader framework on how immune genetics affect peptide choices, see our complete guide to Thymosin Alpha-1 dosage and immune modulation, which covers the same immune-gene ground in more depth. And if you are building a full longevity stack, our best peptides for anti-aging in 2026 overview covers where thymulin fits relative to Epithalon, GHK-Cu, and SS-31.
The PeptidesDNA report covers the immune-recognition, longevity, inflammation and zinc-handling markers described above. Upload your existing 23andMe or AncestryDNA file at /upload or order a saliva kit at /order-kit to get your full immune aging panel. You can also view the full thymulin peptide profile including sourcing considerations and mechanism summary.
Verdict: Thymulin is the most upstream immune aging peptide in the research pipeline, but zinc is where you start. The 50-year body of evidence linking thymulin decline to immune aging is real. The evidence that exogenous thymulin in humans restores measurable immune function is not there yet in controlled form. Fix zinc deficiency first, assess your immune genetics, and consider Thymosin Alpha-1 as the near-term bridge with actual human trial data while thymulin research matures. Knowing where you sit on the immune-recognition, inflammation and zinc-handling markers above tells you how big the job is and how early it started; it does not tell you how you would respond to the peptide, which nobody has measured. Test your immune genetics at /upload or order a kit.
Frequently asked questions
What does thymulin actually do in the body?
Thymulin is a hormone produced by thymic epithelial cells that guides the maturation of immature T-cells (thymocytes) into functional immune cells. It switches on the surface markers (CD4 and CD8) that give a T-cell its identity and job. Without adequate thymulin, thymocytes cannot complete their education inside the thymus and either fail to become functional T-cells or are deleted. Thymulin also has anti-inflammatory and analgesic properties shown in animal research, suggesting it acts in tissues outside the thymus as well.
Why does thymulin go to zero as you age?
Thymulin is made only by thymic epithelial cells, and the thymus undergoes a process called involution starting in early adulthood. Active thymic tissue is progressively replaced by adipose (fat) tissue, shrinking the population of thymulin-producing cells. By age 60, most people have so little functional thymic tissue remaining that thymulin output falls below detection by standard bioassay. The process is driven by hormonal changes, inflammatory signals, and oxidative stress on thymic cells over decades.
Can zinc supplementation restore thymulin?
Partially, in zinc-deficient individuals. Thymulin requires zinc to be biologically active. Without zinc it circulates as inactive apothymulin, which standard tests cannot detect. Research by Mocchegiani and colleagues found that zinc supplementation in zinc-deficient elderly subjects restored some detectable active thymulin. This does not rebuild the thymus or restore production to youthful levels, but it may recover meaningful activity that zinc deficiency was suppressing. Testing serum zinc before assuming complete thymulin failure is sensible.
What is the difference between thymulin and Thymosin Alpha-1?
Thymulin acts upstream in the T-cell maturation process inside the thymus, training thymocytes into functional T-cells. Thymosin Alpha-1 is a 28-amino-acid peptide that acts on already-mature immune cells, shifting the response toward the arm of the immune system that handles viruses and cancerous cells. Thymosin Alpha-1 has over 30 completed controlled trials in humans and is approved in 35 countries. Thymulin has no completed controlled human trials for immune restoration. In practical terms: Thymosin Alpha-1 has far more human evidence. Thymulin is further upstream biologically but further behind on clinical validation.
What is zinc-thymulin and why is it used for hair loss?
Zinc-thymulin refers to the active zinc-bound form of the thymulin peptide. Hair follicle dermal papilla cells express thymulin receptors, and early research found that thymulin signaling promotes follicle survival and hair cycle progression. Compounding clinics have developed zinc-thymulin formulas applied topically or by intradermal injection as an androgenic alopecia treatment. This hair loss application operates through follicle biology rather than T-cell education. The two applications are mechanistically separate, though both rely on the same peptide in its active zinc-bound form.
Is thymulin available as a research peptide and what do clinics dose it at?
Thymulin is available from research peptide suppliers as an injectable nonapeptide. It does not have FDA approval for any indication and is not currently eligible for compounding under US pharmacy rules, placing it in research-peptide-only status. Clinics that use it tend to dose at 200 to 500 mcg subcutaneous, sometimes weekly or in monthly cycles, but these are empirical protocols without human trial validation behind them. Animal research used nanogram-per-kilogram dosing ranges that do not translate cleanly to human protocols. Anyone using thymulin should treat it as an investigational compound.
How do genetics affect thymulin response?
Your HLA genes set how broad a range of threats the T-cells thymulin trained can recognise, which caps immune effectiveness whatever your thymulin level. Versions of the IL-6 inflammation gene that run high go with a faster-shrinking thymus, so your own decline curve may sit ahead of the average. Certain FOXO3 versions, the ones common in people who reach 100, go with slower thymic ageing. Zinc transporter genes affect how well you handle zinc, and since thymulin needs zinc to work at all, that is the one worth acting on: get zinc measured. None of these has been tested against response to thymulin itself.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.